PB:
Genmab Improves its 2021 Financial Guidance
Company Announcement
Genmab improves its 2021 financial guidance
COPENHAGEN, Denmark; November 4, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2021 financial guidance published on August 11, 2021. The improved guidance is driven primarily by increased royalty revenue related to the net sales of DARZALEX® (daratumumab), both intravenous and subcutaneous formulations, and lower operating expense resulting from timing of investments for R&D activities and organizational capability build.
Genmab’s projected revenue for 2021 primarily consists of DARZALEX royalties. Such royalties are based on Genmab’s revised estimate of DARZALEX 2021 net sales of USD 5.9–6.2 billion compared to Genmab’s previous estimate of USD 5.6-5.9 billion.
Revised Previous
(DKK million) Guidance Guidance
Revenue 7,900 - 8,500 7,300 - 7,900
Operating expenses (5,300) - (5,600) (5,500) - (5,800)
Operating result 2,300 - 3,200 1,500 - 2,400
Genmab’s financial results for the first nine months of 2021 will be published on November 10, 2021.
The above expectations are based on assumptions including those described on pages 5 and 6 of the Interim Report for the First Half of 2021 (Company Announcement No. 60 / 2021).